Another update on ... - THE "NEW" PROSTATE CANCER INFOLINK
Exelexis has issued a media release stating that ?the pre-specified number of progression-free survival (PFS) events required for un-blinding of the data for the ongoing Phase III pivotal trial of cabozantinib in patients with medullary thyroid cancer (MTC), known as the EXAM trial, has been reached.?
If this information leads to a further announcement that the initial results of the EXAM trial are positive, and if the U.S. Food & Drug Administration approves cabozantinib for the treatment of patients with unresectable, locally advanced, or metastatic MTC on the basis of these data, this would also make cabozantinib available for the treatment of men with metastatic, castration-resistant prostate cancer (mCRPC) at some time relatively early in 2012. Whether one?s insurance provider would cover the costs of treatment of prostate cancer with cabozantinib is not quite so certain.
Exelexis notes in its media release that the company is still planning to initiate a randomized, double-blind, Phase III of cabozantinib in treatment of CRPC and/or mCRPC at some time later this year. Furthermore, a new Phase II clinical trial of cabozantinib in men with mCRPC to bone has been initiated at the University of Michigan and should start to enroll patients in October this year. This latter study is not a randomized clinical trial, and all patients in this study will receive cabozantinib.
Like this:
Be the first to like this post.
Filed under: Drugs in development, Management, Treatment Tagged: | cabozantinib, castration-resistant, metastatic
Source: http://prostatecancerinfolink.net/2011/09/07/another-update-on-cabozantinib-xl-184/
fallen terminator salvation terminator salvation chelsea chelsea iowa state fair iowa state fair